Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Signal Detection of DPP-IV Inhibitors using Spontaneous Adverse Event Reporting System in Korea

자발적 부작용 보고 데이터베이스를 이용한 DPP- IV inhibitor의 약물이상사례 분석

  • Hyejung Pyo (College of Pharmacy and the Graduate School of Converging Clinical & Public Health, Ewha Womans University) ;
  • Tae Young Kim (College of Pharmacy, Chungbuk National University) ;
  • Su Been Choi (College of Pharmacy, Chungbuk National University) ;
  • Hyeong Jun Jo (College of Pharmacy, Chungbuk National University) ;
  • Hae Lee Kang (College of Pharmacy, Chungbuk National University) ;
  • Jung Sun Kim (College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University) ;
  • Hye Sun Gwak (College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University) ;
  • Ji Min Han (College of Pharmacy, Chungbuk National University)
  • 표혜정 (이화여자대학교 임상보건융합대학원) ;
  • 김태영 (충북대학교 약학대학) ;
  • 최수빈 (충북대학교 약학대학) ;
  • 조형준 (충북대학교 약학대학) ;
  • 강해리 (충북대학교 약학대학) ;
  • 김정선 (이화여자대학교 약학대학) ;
  • 곽혜선 (이화여자대학교 약학대학) ;
  • 한지민 (충북대학교 약학대학)
  • Received : 2024.03.24
  • Accepted : 2024.05.23
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The purpose of this study was to detect signals of adverse events (AEs) of DPP-IV inhibitors using the KIDs-Korea Adverse Event Reporting System (KAERS) database. Methods: This study was conducted using AEs reported from January 2009 to December 2018 in the KIDs-KAERS database. For signal detection, disproportionality analysis was performed. Signals of DPP-IV inhibitor that satisfied the data-mining indices of reporting odds ratio (ROR) were detected. Results: Among the total number of 10,364 AEs to all oral hypoglycemic agents, the number of reported AEs related to DPP-IV inhibitors was 1,674. Analysis of reported AEs of DPP-IV inhibitors at the SOC levels showed that Respiratory system disorders were the highest at 4.31 (95% CI 3.01-6.17), followed by Skin and appendages disorders at 2.04 (95% CI 1.74-2.38). When analyzing AEs reported at the PT level, pharyngitis was the highest at 73.90 (95% CI 17.59-310.49), followed by arthralgia at 6.08 (95% CI 2.04-18.11), and coughing at 5.21 (95% CI 2.07-13.15). Conclusions: Based on the result of the study, deeper consideration is required according to the characteristics of the patients in prescribing DPP-IV inhibitors among oral hypoglycemic agents, and continuous monitoring of the occurrence of related Adverse Drug Reactions during administration is also required.

Keywords

Acknowledgement

이 논문은 2020학년도 충북대학교 학술연구지원사업의 연구비 지원에 의해 연구되었음.

References

  1. Gwon HS. Treatment Guideline for Diabetes, 6th edition. Journal of Korean Diabetes, 2019:57-58.
  2. Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther 2012;37(5):510-24.
  3. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systemiatic review and meta-analysis. JAMA 2007;298:194-206.
  4. Mendonca F, Martin-Gutierrez F, Rios-Martin J, Camacho-Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors - one due to linagliptin. Dermatology 2016;232:249-53.
  5. Yi H, Lee JH, Shin JY. Signal Detection for Cardiovascular Adverse Events of DPP-IV Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016. Yonsei Med J 2019;60(2):200-7.
  6. Pinto LC, Rados D, Barkan S, Leitao C, Gross J. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 2018;8(1):782.
  7. Kim NH. Comparison of DPP-IV inhibitors. J Korean Diabetes 2013;14:111-9.
  8. Seo J, Lee J, Chae G, Lee S, Jung R, Shin W. Application of electronic data standard for drug safety reporting in Korea. J Health Info Stat 2017;42(3):199-207.
  9. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007;40(4):278-84.
  10. Kim S, Wang B, Lee J, et al. Statistical analysis system of spontaneous adverse drug reaction reports. J Korean Soc Clin Pharmacol Ther 2012;20(2):155-64.
  11. Sato K, Mano T, Iwata A, Toda T. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database. J Neurooncol 2019;145:1-9.
  12. Kathleen R. Richard. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33;1609-29.
  13. Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol 2020;21(1):68.
  14. Wilemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization vigibase. Diabetes Care 2011;34:369-74.
  15. Varpuluoma O, Forsti AK, Jokelainen J, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a finnish nationwide registry study. J Invest Dermatol 2018;138(7):1659-61.
  16. Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol 2018;154(10):1152-58.
  17. Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019;155(2):172-7.
  18. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019;4(10):1238.
  19. Gonzalez-Gronow M, Kaczowka S, Gawdi G, PizzoSV. Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci 2008;13:1610-18.
  20. Hofmann SC, Voith U, Schonau V, Bruckner-Tuderman L, Franzke C. Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. J Invest Dermatol 2009;129:1730-9.
  21. Men P, et al. Dipeptidyl Peptidase-4 Inhibitors and Risk of Arthralgia: A Systematic Review and Meta-analysis. Diabetes Metab 2017:493-500.